Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

1 in 2 May Be Infected. So How Do You Know If You Have H. pylori?
2026-09-29

In China, the prevalence of Helicobacter pylori (H. pylori, or Hp) infection is as high as 40%–50%, meaning that nearly one in two people may be infected. H. pylori infection is a major cause of chronic gastritis, peptic ulcers, and gastric cancer, making accurate diagnosis the first step toward effective management. In July 2026, the Helicobacter pylori Study Group of […]

LEARN MORE
From Viral Detection to Cancer Prevention The Role of NAT in HBV, HCV and HIV Management
2026-09-11

When cancer is mentioned, people often think of genetics, environmental factors or unhealthy lifestyles. However, what may be less known is that approximately 15%-20% of cancer cases worldwide can be attributed to chronic viral infections. Among these pathogens, HBV and HCV are major viral drivers of Hepatocellular Carcinoma (HCC), while HIV-associated immunodeficiency substantially increases the risk of several AIDS-defining and […]

LEARN MORE
Why Higher Sensitivity HPV Testing Is Critical for Screen-and-Treat Strategies in Resource-Limited Settings
2025-06-20

In low- and middle-income countries (LMICs), cervical cancer remains a leading cause of mortality, with 85% of global deaths occurring in regions where healthcare access is constrained and follow-up care is unreliable. High-sensitivity HPV testing emerges as a cornerstone of screen-and-treat strategies, addressing systemic challenges through four interlocking mechanisms:   1. First Detection = Last Detection: Maximizing the Impact of Single Screening […]

LEARN MORE
Clinical Management and Treatment of Viral Hepatitis Co-infections in HIV-Positive Individuals
2024-09-24

Viral hepatitis co-infections, particularly hepatitis B (HBV) and hepatitis C (HCV), are significant comorbidities in people living with HIV (PLWH). The European AIDS Clinical Society (EACS) guidelines provide comprehensive recommendations for screening, monitoring, and treating these co-infections to improve patient outcomes and reduce the risk of liver-related complications.   Screening and Diagnosis: The guidelines emphasize the importance of routine screening […]

LEARN MORE
HCV Screening and Treatment: Critical for High-Risk Chronic Kidney Disease Patients
2024-08-29

Chronic Kidney Disease (CKD) patients are at high risk for Hepatitis C Virus (HCV) infection. Screening and treatment monitoring have become crucial in managing this vulnerable population. As a leader in diagnostic solutions, Sansure Biotech is committed to supporting healthcare providers in addressing this critical health issue.   The Link Between CKD and HCV CKD is a global health concern, […]

LEARN MORE
1 2 3 … 12
×
Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.
SUBMIT

Thank you!

We shall contact you soon!
Back Top